after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current operating plans, Metsera estimates its existing cash and cash equivalents will ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. MetseraMTSR just cleared that benchmark with an upgrade from 66 to 84. Please watch the video at ...

Shares of Graham Corporation GHM surged around 9% on Monday after the company reported better-than-expected fourth-quarter ...

The media giant announced on Monday that it will divide into two entities: one focused on streaming and studios—housing its film assets and HBO Max—and another dedicated to global networks, including ...

Additionally, Metsera is accelerating its oral formulation program for MET-097o, with outcomes anticipated in late 2025. The recent $316 million IPO will support operations through 2027 as the ...

after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current operating plans, Metsera estimates its existing cash and cash equivalents will ...

Cash Position: Cash and cash equivalents were $588.3 million as of March 31, 2025, after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current ...

Metsera, Inc. is the "new kid on the block" in the GLP-receptor agonist weight loss drug field. The recently IPO'd company has an injectable at the Phase 2b study stage, with data promised this ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...